Astel­las pres­i­dent jumps to a new Fron­tier; Gri­fols chair­man named CEO, break­ing fam­i­ly tra­di­tion

→ An­drew Krivoshik has jumped ship at Astel­las to be­come CMO at Fron­tier Med­i­cines, a sub­stan­tial get for Chris Var­ma and his pre­ci­sion med­i­cines crew fo­cused on un­drug­gables. Krivoshik joined Astel­las from Ab­bott in 2011 and was the on­col­o­gy ther­a­peu­tic area head at the Japan­ese phar­ma when the Seagen-part­nered an­ti­body-drug con­ju­gate Pad­cev notched a full FDA ap­proval in 2021.

Since then, Krivoshik as­cend­ed to SVP and head of de­vel­op­ment ther­a­peu­tic ar­eas, and then pres­i­dent and head of de­vel­op­ment in April 2022. Ab­b­Vie paid $55 mil­lion up­front in a De­cem­ber 2020 pro­tein degra­da­tion pact with Fron­tier, which wants to chal­lenge Am­gen and Mi­rati in the KRAS space.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN